Private Advisor Group LLC Has $397,000 Stock Position in Natera, Inc. (NASDAQ:NTRA)

Private Advisor Group LLC reduced its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 7.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,511 shares of the medical research company’s stock after selling 210 shares during the period. Private Advisor Group LLC’s holdings in Natera were worth $397,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of NTRA. Chartwell Investment Partners LLC grew its stake in shares of Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after buying an additional 11,362 shares in the last quarter. Cerity Partners LLC raised its stake in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Natera in the third quarter valued at about $385,000. Everence Capital Management Inc. acquired a new position in Natera during the fourth quarter worth about $573,000. Finally, First Turn Management LLC acquired a new position in shares of Natera in the third quarter valued at approximately $19,760,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Natera

In related news, insider Solomon Moshkevich sold 4,858 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22. Following the completion of the sale, the insider now directly owns 114,912 shares in the company, valued at approximately $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Fesko sold 669 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total transaction of $106,772.40. Following the completion of the sale, the insider now owns 114,142 shares of the company’s stock, valued at approximately $18,217,063.20. The trade was a 0.58 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 208,299 shares of company stock valued at $34,948,265. Corporate insiders own 7.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on NTRA. Sanford C. Bernstein upped their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, January 10th. JPMorgan Chase & Co. increased their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Morgan Stanley raised their target price on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Barclays started coverage on Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price for the company. Finally, Craig Hallum increased their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Natera Trading Down 0.5 %

Shares of NASDAQ:NTRA opened at $142.35 on Wednesday. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The business’s fifty day simple moving average is $167.06 and its 200-day simple moving average is $147.50. The company has a market capitalization of $18.79 billion, a PE ratio of -80.88 and a beta of 1.66. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.